Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jeffrey S Barrett, Ph.D.

Title
Institution
Department
Address

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. RC1LM010367 (BARRETT, JEFFREY SCOTT) Sep 30, 2009 - Sep 29, 2012
    NIH/NLM
    DECISION SUPPORT SYSTEM TO GUIDE PEDIATRIC PHARMACOTHERAPY
    Role: Principal Investigator
  2. U10HD037255 (BARRETT, JEFFREY SCOTT) Jan 7, 1999 - Dec 31, 2010
    NIH/NICHD
    Pediatric Pharmacology Research Unit Network
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019 03; 38(13):2241-2262. PMID: 30478448.
    Citations:    
  2. Watt KM, Cohen-Wolkowiez M, Barrett JS, Sevestre M, Zhao P, Brouwer KLR, Edginton AN. Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO. CPT Pharmacometrics Syst Pharmacol. 2018 Oct; 7(10):629-637. PMID: 30033691.
    Citations:    
  3. Brussee JM, Yu H, Krekels EHJ, Palic S, Brill MJE, Barrett JS, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. Pharm Res. 2018 Jul 30; 35(9):182. PMID: 30062590.
    Citations:    
  4. Kaddi CD, Niesner B, Baek R, Jasper P, Pappas J, Tolsma J, Li J, van Rijn Z, Tao M, Ortemann-Renon C, Easton R, Tan S, Puga AC, Schuchman EH, Barrett JS, Azer K. Quantitative Systems Pharmacology Modeling of Acid Sphingomyelinase Deficiency and the Enzyme Replacement Therapy Olipudase Alfa Is an Innovative Tool for Linking Pathophysiology and Pharmacology. CPT Pharmacometrics Syst Pharmacol. 2018 Jul; 7(7):442-452. PMID: 29920993.
    Citations:    
  5. van Rongen A, Brill MJE, Vaughns JD, Välitalo PAJ, van Dongen EPA, van Ramshorst B, Barrett JS, van den Anker JN, Knibbe CAJ. Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. Clin Pharmacokinet. 2018 05; 57(5):601-611. PMID: 28785981.
    Citations:    
  6. Bajaj G, Gupta M, Wang HH, Barrett JS, Tan M, Rupalla K, Bertz R, Sheng J. Challenges and Opportunities With Oncology Drug Development in China. Clin Pharmacol Ther. 2019 Feb; 105(2):363-375. PMID: 29328503.
    Citations:    
  7. Barrett JS, Bishai R, Bucci-Rechtweg C, Cheung A, Corriol-Rohou S, Haertter S, James A, Kovacs SJ, Liu J, Potempa D, Strougo A, Vanevski K. Challenges and Opportunities in the Development of Medical Therapies for Pediatric Populations and the Role of Extrapolation. Clin Pharmacol Ther. 2018 03; 103(3):419-433. PMID: 29277892.
    Citations:    
  8. Mulugeta LY, Yao L, Mould D, Jacobs B, Florian J, Smith B, Sinha V, Barrett JS. Leveraging Big Data in Pediatric Development Programs: Proceedings From the 2016 American College of Clinical Pharmacology Annual Meeting Symposium. Clin Pharmacol Ther. 2018 Jul; 104(1):81-87. PMID: 29319159.
    Citations:    
  9. Spitsin S, Tebas P, Barrett JS, Pappa V, Kim D, Taylor D, Evans DL, Douglas SD. Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults. JCI Insight. 2017 10 05; 2(19). PMID: 28978797.
    Citations:    
  10. McQuade ST, Abrams RE, Barrett JS, Piccoli B, Azer K. Linear-In-Flux-Expressions Methodology: Toward a Robust Mathematical Framework for Quantitative Systems Pharmacology Simulators. Gene Regul Syst Bio. 2017; 11:1177625017711414. PMID: 29581702.
    Citations:    
  11. Ming JE, Abrams RE, Bartlett DW, Tao M, Nguyen T, Surks H, Kudrycki K, Kadambi A, Friedrich CM, Djebli N, Goebel B, Koszycki A, Varshnaya M, Elassal J, Banerjee P, Sasiela WJ, Reed MJ, Barrett JS, Azer K. A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics. Gene Regul Syst Bio. 2017; 11:1177625017710941. PMID: 28804243.
    Citations:    
  12. Ward RM, Benjamin D, Barrett JS, Allegaert K, Portman R, Davis JM, Turner MA. Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. Pediatr Res. 2017 May; 81(5):692-711. PMID: 28248319.
    Citations:    
  13. Mulugeta Y, Barrett JS, Nelson R, Eshete AT, Mushtaq A, Yao L, Glasgow N, Mulberg AE, Gonzalez D, Green D, Florian J, Krudys K, Seo S, Kim I, Chilukuri D, Burckart GJ. Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development. J Clin Pharmacol. 2016 11; 56(11):1326-1334. PMID: 27040726.
    Citations:    
  14. Barrett JS, Spitsin S, Moorthy G, Barrett K, Baker K, Lackner A, Tulic F, Winters A, Evans DL, Douglas SD. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med. 2016 05 26; 14(1):148. PMID: 27230663.
    Citations:    
  15. van Rongen A, Vaughns JD, Moorthy GS, Barrett JS, Knibbe CA, van den Anker JN. Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. Br J Clin Pharmacol. 2015 Nov; 80(5):1185-96. PMID: 26044579.
    Citations:    
  16. Barrett JS, Hirankarn S, Holford N, Hammer GB, Drover DR, Cohane CA, Anderson B, Dombrowski E, Reece T, Zajicek A, Schulman SR. A hemodynamic model to guide blood pressure control during deliberate hypotension with sodium nitroprusside in children. Front Pharmacol. 2015; 6:151. PMID: 26283961.
    Citations:    
  17. Ng CM, Dombrowsky E, Lin H, Erlich ME, Moody DE, Barrett JS, Kraft WK. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome. Pharmacotherapy. 2015 Jul; 35(7):670-80. PMID: 26172282.
    Citations:    
  18. Drover DR, Hammer GB, Barrett JS, Cohane CA, Reece T, Zajicek A, Schulman SR. Evaluation of sodium nitroprusside for controlled hypotension in children during surgery. Front Pharmacol. 2015; 6:136. PMID: 26217225.
    Citations:    
  19. Harskamp-van Ginkel MW, Hill KD, Becker KC, Becker K, Testoni D, Cohen-Wolkowiez M, Gonzalez D, Barrett JS, Benjamin DK, Siegel DA, Banks P, Watt KM. Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review. JAMA Pediatr. 2015 Jul; 169(7):678-85. PMID: 25961828.
    Citations:    
  20. Tebas P, Spitsin S, Barrett JS, Tuluc F, Elci O, Korelitz JJ, Wagner W, Winters A, Kim D, Catalano R, Evans DL, Douglas SD. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS. 2015 May 15; 29(8):931-9. PMID: 25915168.
    Citations:    
  21. Mascarenhas MR, Mondick J, Barrett JS, Wilson M, Stallings VA, Schall JI. Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiency. J Clin Pharmacol. 2015 Aug; 55(8):854-65. PMID: 25689042.
    Citations:    
  22. Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, Gupta M. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol. 2015 Mar; 55 Suppl 3:S103-15. PMID: 25707958.
    Citations:    
  23. Huang Z, Barrett JS, Barrett K, Barrett R, Ng CM. Novel method to predict body weight in children based on age and morphological facial features. J Clin Pharmacol. 2015 Apr; 55(4):447-51. PMID: 25370186.
    Citations:    
  24. Barrett JS. Paediatric models in motion: requirements for model-based decision support at the bedside. Br J Clin Pharmacol. 2015 Jan; 79(1):85-96. PMID: 24251868.
    Citations:    
  25. McGuire JL, Barrett JS, Vezina HE, Spitsin S, Douglas SD. Adjuvant therapies for HIV-associated neurocognitive disorders. Ann Clin Transl Neurol. 2014 Nov; 1(11):938-52. PMID: 25540809.
    Citations:    
  26. Spielberg DR, Barrett JS, Hammer GB, Drover DR, Reece T, Cohane CA, Schulman SR. Predictors of arterial blood pressure control during deliberate hypotension with sodium nitroprusside in children. Anesth Analg. 2014 Oct; 119(4):867-74. PMID: 25099924.
    Citations:    
  27. Zuo XC, Zhang WL, Yuan H, Barrett JS, Hua Y, Huang ZJ, Zhou HH, Pei Q, Guo CX, Wang JL, Yang GP. ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. Drug Metab Pharmacokinet. 2014; 29(4):305-11. PMID: 24522199.
    Citations:    
  28. Barrett JS, Bajaj G, McGuire J, Wu D, Spitsin S, Moorthy G, Zhao X, Tebas P, Evans DL, Douglas SD. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant. Curr HIV Res. 2014; 12(2):121-31. PMID: 24862330.
    Citations:    
  29. Zajicek A, Barrett JS. The grand challenges in obstetric and pediatric pharmacology. Front Pharmacol. 2013; 4:170. PMID: 24416021.
    Citations:    
  30. Barrett JS, McGuire J, Vezina H, Spitsin S, Douglas SD. PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions? J Clin Psychopharmacol. 2013 Dec; 33(6):725-8. PMID: 24100788.
    Citations:    
  31. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH. Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. Clin Cancer Res. 2014 Feb 01; 20(3):754-63. PMID: 24218510.
    Citations:    
  32. Marier JF, Mangum B, Reid B, Barrett JS. A Modeling and Simulations Framework to Support Global Regulatory Strategies for Pediatric Drug Development Programs. Ther Innov Regul Sci. 2013 Sep; 47(5):550-556. PMID: 30235575.
    Citations:    
  33. Zajicek A, Fossler MJ, Barrett JS, Worthington JH, Ternik R, Charkoftaki G, Lum S, Breitkreutz J, Baltezor M, Macheras P, Khan M, Agharkar S, MacLaren DD. A report from the pediatric formulations task force: perspectives on the state of child-friendly oral dosage forms. AAPS J. 2013 Oct; 15(4):1072-81. PMID: 23907486.
    Citations:    
  34. Hirankarn S, Barrett JS, Alamuddin N, FitzGerald GA, Skarke C. GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies. Clin Pharmacol Drug Dev. 2013 Oct; 2(4):379-86. PMID: 27121942.
    Citations:    
  35. Barbarich-Marsteller NC, Underwood MD, Foltin RW, Myers MM, Walsh BT, Barrett JS, Marsteller DA. Identifying novel phenotypes of vulnerability and resistance to activity-based anorexia in adolescent female rats. Int J Eat Disord. 2013 Nov; 46(7):737-46. PMID: 23853140.
    Citations:    
  36. Bajaj G, Dombrowsky E, Yu Q, Agarwal B, Barrett JS. Considerations for the prediction of survival time in pancreatic cancer based on registry data. J Pharmacokinet Pharmacodyn. 2013 Aug; 40(4):527-36. PMID: 23846417.
    Citations:    
  37. Srivastava P, Moorthy GS, Gross R, Barrett JS. A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma. PLoS One. 2013; 8(6):e63305. PMID: 23755102.
    Citations:    
  38. Zuo XC, Ng CM, Barrett JS, Luo AJ, Zhang BK, Deng CH, Xi LY, Cheng K, Ming YZ, Yang GP, Pei Q, Zhu LJ, Yuan H, Liao HQ, Ding JJ, Wu D, Zhou YN, Jing NN, Huang ZJ. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics. 2013 May; 23(5):251-61. PMID: 23459029.
    Citations:    
  39. Barrett JS, Patel D, Dombrowsky E, Bajaj G, Skolnik JM. Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients. AAPS J. 2013 Jul; 15(3):775-86. PMID: 23595361.
    Citations:    
  40. Stallings VA, Mondick JT, Schall JI, Barrett JS, Wilson M, Mascarenhas MR. Diagnosing malabsorption with systemic lipid profiling: pharmacokinetics of pentadecanoic acid and triheptadecanoic acid following oral administration in healthy subjects and subjects with cystic fibrosis. Int J Clin Pharmacol Ther. 2013 Apr; 51(4):263-73. PMID: 23357842.
    Citations:    
  41. Zuo XC, Zhou YN, Zhang BK, Yang GP, Cheng ZN, Yuan H, Ouyang DS, Liu SK, Barrett JS, Li PJ, Liu Z, Tan HY, Guo R, Zhou LY, Xie YL, Li ZJ, Li J, Wang CJ, Wang JL. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug Metab Pharmacokinet. 2013; 28(5):398-405. PMID: 23438946.
    Citations:    
  42. Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood. 2013 Apr 04; 121(14):2689-703. PMID: 23393050.
    Citations:    
  43. McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol. 2013 Mar; 53(3):264-75. PMID: 23444282.
    Citations:    
  44. Bai JP, Barrett JS, Burckart GJ, Meibohm B, Sachs HC, Yao L. Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. AAPS J. 2013 Apr; 15(2):447-54. PMID: 23334978.
    Citations:    
  45. Gerbeth K, Hüsch J, Meins J, Rossi A, Sautebin L, Wiechmann K, Werz O, Skarke C, Barrett JS, Schubert-Zsilavecz M, Abdel-Tawab M. Myrtucommulone from Myrtus communis: metabolism, permeability, and systemic exposure in rats. Planta Med. 2012 Dec; 78(18):1932-8. PMID: 23150076.
    Citations:    
  46. Zuo XC, Yuan H, Zhang BK, Ng CM, Barrett JS, Yang GP, Huang ZJ, Pei Q, Guo R, Zhou YN, Jing NN, Di W. [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. Yao Xue Xue Bao. 2012 Jul; 47(7):941-6. PMID: 22993862.
    Citations:    
  47. Edwards AY, Skolnik JM, Dombrowsky E, Patel D, Barrett JS. Modeling and simulation approaches to evaluate pharmacokinetic sampling contamination from central venous catheters in pediatric pharmacokinetic studies of actinomycin-D: a report from the children's oncology group. Cancer Chemother Pharmacol. 2012 Jul; 70(1):83-94. PMID: 22623208.
    Citations:    
  48. Rowan CG, Brunelli SM, Munson J, Flory J, Reese PP, Hennessy S, Lewis J, Mines D, Barrett JS, Bilker W, Strom BL. Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network. Pharmacoepidemiol Drug Saf. 2012 May; 21(5):494-506. PMID: 22422642.
    Citations: 7     Fields:    Translation:Humans
  49. Gooneratne NS, Edwards AY, Zhou C, Cuellar N, Grandner MA, Barrett JS. Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults. J Pineal Res. 2012 May; 52(4):437-45. PMID: 22348451.
    Citations:    
  50. Williams JH, Jayaraman B, Swoboda KJ, Barrett JS. Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients. J Clin Pharmacol. 2012 Nov; 52(11):1676-88. PMID: 22167565.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  51. Skarke C, Kuczka K, Tausch L, Werz O, Rossmanith T, Barrett JS, Harder S, Holtmeier W, Schwarz JA. Increased bioavailability of 11-keto-ß-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: modeling and simulation considerations for evaluating drug exposures. J Clin Pharmacol. 2012 Oct; 52(10):1592-600. PMID: 22167571.
    Citations:    
  52. Zuppa AF, Hammer GB, Barrett JS, Kenney BF, Kassir N, Mouksassi S, Royal MA. Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J Pediatr Pharmacol Ther. 2011 Oct; 16(4):246-61. PMID: 22768009.
    Citations:    
  53. Tebas P, Tuluc F, Barrett JS, Wagner W, Kim D, Zhao H, Gonin R, Korelitz J, Douglas SD. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults. PLoS One. 2011; 6(9):e24180. PMID: 21931661.
    Citations:    
  54. Maitland ML, Bies RR, Barrett JS. A time to keep and a time to cast away categories of tumor response. J Clin Oncol. 2011 Aug 10; 29(23):3109-11. PMID: 21730274.
    Citations:    
  55. Zuppa AF, Nicolson SC, Barrett JS, Gastonguay MR. Population pharmacokinetics of pentobarbital in neonates, infants, and children after open heart surgery. J Pediatr. 2011 Sep; 159(3):414-419.e1-3. PMID: 21665222.
    Citations:    
  56. Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Hope WW, Wade KC, Cohen-Wolkowiez M, Benjamin DK. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J. 2011 May; 30(5):375-8. PMID: 21085048.
    Citations:    
  57. Barrett JS, Narayan M, Patel D, Zuppa AF, Adamson PC. Prescribing habits and caregiver satisfaction with resources for dosing children: rationale for more informative dosing guidance. BMC Pediatr. 2011 Apr 02; 11:25. PMID: 21457572.
    Citations:    
  58. Dombrowsky E, Jayaraman B, Narayan M, Barrett JS. Evaluating performance of a decision support system to improve methotrexate pharmacotherapy in children and young adults with cancer. Ther Drug Monit. 2011 Feb; 33(1):99-107. PMID: 21192315.
    Citations:    
  59. Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A, Arndt CA. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Aug; 57(2):252-7. PMID: 21671362.
    Citations:    
  60. Skolnik JM, Zhang AY, Barrett JS, Adamson PC. Approaches to clear residual chemotherapeutics from indwelling catheters in children with cancer. Ther Drug Monit. 2010 Dec; 32(6):741-8. PMID: 20962707.
    Citations:    
  61. Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, Godinez RI, Zuppa AF. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg. 2010 May 01; 110(5):1383-92. PMID: 20418300.
    Citations:    
  62. Marsenic O, Zhang L, Zuppa A, Barrett JS, Pfister M. Application of Individualized Bayesian Urea Kinetic Modeling to pediatric hemodialysis. ASAIO J. 2010 May-Jun; 56(3):246-53. PMID: 20168209.
    Citations:    
  63. Wu D, Wade KC, Paul DJ, Barrett JS. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther Drug Monit. 2009 Dec; 31(6):703-9. PMID: 19745791.
    Citations:    
  64. Mondick JT, Johnson BM, Haberer LJ, Sale ME, Adamson PC, Coté CJ, Croop JM, Russo MW, Barrett JS, Hoke JF. Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. Eur J Clin Pharmacol. 2010 Jan; 66(1):77-86. PMID: 19798490.
    Citations:    
  65. Wade KC, Benjamin DK, Kaufman DA, Ward RM, Smith PB, Jayaraman B, Adamson PC, Gastonguay MR, Barrett JS. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009 Aug; 28(8):717-23. PMID: 19593252.
    Citations:    
  66. Läer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol. 2009 Aug; 49(8):889-904. PMID: 19531673.
    Citations:    
  67. Rowan C, Brinker AD, Nourjah P, Chang J, Mosholder A, Barrett JS, Avigan M. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf. 2009 Apr; 18(4):301-9. PMID: 19206087.
    Citations:    
  68. Mondick JT, Oo C, Patel D, Fujitani T, Shimizu K, Barrett JS. Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan. Am J Ther. 2009 Mar-Apr; 16(2):106-15. PMID: 19300037.
    Citations:    
  69. Wu D, Paul DJ, Zhao X, Douglas SD, Barrett JS. A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research. J Pharm Biomed Anal. 2009 Apr 05; 49(3):739-45. PMID: 19167182.
    Citations:    
  70. Gross R, Aplenc R, Tenhave T, Foulkes AS, Thakur R, Mosepele M, Barrett JS, Flexner C, Strom BL, Bisson G. Slow efavirenz metabolism genotype is common in Botswana. J Acquir Immune Defic Syndr. 2008 Nov 01; 49(3):336-7. PMID: 18978480.
    Citations: 15     Fields:    Translation:Humans
  71. Barrett JS, Patel D, Jayaraman B, Narayan M, Zuppa A. Key performance indicators for the assessment of pediatric pharmacotherapeutic guidance. J Pediatr Pharmacol Ther. 2008 Jul; 13(3):141-55. PMID: 23055875.
    Citations:    
  72. Zuppa AF, Barrett JS. Pharmacokinetics and pharmacodynamics in the critically ill child. Pediatr Clin North Am. 2008 Jun; 55(3):735-55, xii. PMID: 18501763.
    Citations:    
  73. Barrett JS, Shi J, Xie HT, Huang XH, Fossler MJ, Sun RY. Globalization of quantitative pharmacology: first international symposium of quantitative pharmacology in drug development and regulation. J Clin Pharmacol. 2008 Jul; 48(7):787-92. PMID: 18490494.
    Citations:    
  74. Barrett JS, Fossler MJ, Cadieu KD, Gastonguay MR. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008 May; 48(5):632-49. PMID: 18440922.
    Citations:    
  75. Adamson PC, Barrett JS. All dex'ed out with nowhere to go? J Clin Oncol. 2008 Apr 20; 26(12):1917-8. PMID: 18421043.
    Citations:    
  76. Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly AD, Willman CL, Carroll AJ, Adamson PC, Barrett JS, Felix CA. Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol. 2008 Jun; 141(6):827-39. PMID: 18422996.
    Citations:    
  77. Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009 Jan; 63(2):229-38. PMID: 18398615.
    Citations:    
  78. Barrett JS, Jayaraman B, Patel D, Skolnik JM. A SAS-based solution to evaluate study design efficiency of phase I pediatric oncology trials via discrete event simulation. Comput Methods Programs Biomed. 2008 Jun; 90(3):240-50. PMID: 18276034.
    Citations:    
  79. Barrett JS. The role of quantitative pharmacology in an academic translational research environment. AAPS J. 2008; 10(1):9-14. PMID: 18446501.
    Citations:    
  80. Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S. Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak. 2008 Jan 28; 8:6. PMID: 18226244.
    Citations:    
  81. Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol. 2008 Jan 10; 26(2):190-5. PMID: 18182661.
    Citations:    
  82. Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC, Barrett JS. Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol. 2008 Jan; 48(1):35-42. PMID: 18094218.
    Citations:    
  83. Sorenmo K, Samluk M, Clifford C, Baez J, Barrett JS, Poppenga R, Overley B, Skorupski K, Oberthaler K, Van Winkle T, Seiler G, Shofer F. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. J Vet Intern Med. 2007 Nov-Dec; 21(6):1347-54. PMID: 18196746.
    Citations:    
  84. Zuppa A, Vijayakumar S, Jayaraman B, Patel D, Narayan M, Vijayakumar K, Mondick JT, Barrett JS. An informatics approach to assess pediatric pharmacotherapy: design and implementation of a hospital drug utilization system. J Clin Pharmacol. 2007 Sep; 47(9):1172-80. PMID: 17656617.
    Citations:    
  85. Lee JI, Skolnik JM, Barrett JS, Adamson PC. A sensitive and selective liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. J Mass Spectrom. 2007 Jun; 42(6):761-70. PMID: 17511020.
    Citations:    
  86. Barrett JS, Gupta M, Mondick JT. Model-based drug development applied to oncology. Expert Opin Drug Discov. 2007 Feb; 2(2):185-209. PMID: 23496077.
    Citations:    
  87. Barrett JS. Facilitating compound progression of antiretroviral agents via modeling and simulation. J Neuroimmune Pharmacol. 2007 Mar; 2(1):58-71. PMID: 18040827.
    Citations:    
  88. Lee JI, Narayan M, Barrett JS. Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jan 01; 845(1):95-103. PMID: 16942922.
    Citations:    
  89. Lee JI, Hsu BH, Wu D, Barrett JS. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr A. 2006 May 26; 1116(1-2):57-68. PMID: 16631762.
    Citations:    
  90. Zuppa AF, Nicolson SC, Adamson PC, Wernovsky G, Mondick JT, Burnham N, Hoffman TM, Gaynor JW, Davis LA, Greeley WJ, Spray TL, Barrett JS. Population pharmacokinetics of milrinone in neonates with hypoplastic left heart syndrome undergoing stage I reconstruction. Anesth Analg. 2006 Apr; 102(4):1062-9. PMID: 16551899.
    Citations:    
  91. Zuppa AF, Adamson PC, Mondick JT, Davis LA, Maka DA, Narayan M, Nicholson C, Patel D, Collison KR, Barrett JS. Drug utilization in the pediatric intensive care unit: monitoring prescribing trends and establishing prioritization of pharmacotherapeutic evaluation of critically ill children. J Clin Pharmacol. 2005 Nov; 45(11):1305-12. PMID: 16239364.
    Citations:    
  92. Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005 Oct 05; 7(2):E475-87. PMID: 16353925.
    Citations:    
  93. Kenna LA, Labbé L, Barrett JS, Pfister M. Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J. 2005 Oct 05; 7(2):E390-407. PMID: 16353919.
    Citations:    
  94. Skolnik JM, Barrett JS, Shi H, Adamson PC. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer. Cancer Chemother Pharmacol. 2006 Apr; 57(4):458-64. PMID: 16187113.
    Citations:    
  95. Barrett JS, Labbé L, Pfister M. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet. 2005; 44(6):591-625. PMID: 15910009.
    Citations:    
  96. Shi J, Pfister M, Jenkins SG, Chapel S, Barrett JS, Port RE, Howard D. Pharmacodynamic analysis of the microbiological efficacy of telithromycin in patients with community-acquired pneumonia. Clin Pharmacokinet. 2005; 44(3):317-29. PMID: 15762772.
    Citations:    
  97. Cirillo I, Martin NE, Brennan B, Barrett JS. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240. J Clin Pharmacol. 2004 Dec; 44(12):1379-84. PMID: 15545308.
    Citations:    
  98. Pfister M, Martin NE, Haskell LP, Barrett JS. Optimizing dose selection with modeling and simulation: application to the vasopeptidase inhibitor M100240. J Clin Pharmacol. 2004 Jun; 44(6):621-31. PMID: 15145970.
    Citations:    
  99. Martin NE, Howell SR, Martin LL, Cirillo I, Barrett JS. No clinically relevant CYP3A induction with the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240. J Clin Pharmacol. 2004 Apr; 44(4):379-87. PMID: 15051745.
    Citations:    
  100. Shi J, Montay G, Chapel S, Hardy P, Barrett JS, Sack M, Marbury T, Swan SK, Vargas R, Leclerc V, Leroy B, Bhargava VO. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol. 2004 Mar; 44(3):234-44. PMID: 14973302.
    Citations:    
  101. Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J Clin Pharmacol. 2003 Jul; 43(7):727-34. PMID: 12856386.
    Citations:    
  102. Martin NE, Collison KR, Martin LL, Tardif S, Wilding I, Wray H, Barrett JS. Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers. J Clin Pharmacol. 2003 May; 43(5):529-38. PMID: 12751274.
    Citations:    
  103. Fossler MJ, Ebling WF, Ma S, Kornhauser D, Mondick J, Barrett JS, Garner D, Quon CY, Pieniaszek HJ. Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers. J Clin Pharmacol. 2002 Dec; 42(12):1326-34. PMID: 12463727.
    Citations:    
  104. Hainer JW, Sherrard DJ, Swan SK, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Williams RM, Pittenger AL, Stephenson CA, Hua TA. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis. Am J Kidney Dis. 2002 Sep; 40(3):531-8. PMID: 12200805.
    Citations:    
  105. Hainer JW, Barrett JS, Assaid CA, Fossler MJ, Cox DS, Leathers T, Leese PT. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002 May; 87(5):817-23. PMID: 12038783.
    Citations:    
  106. Barrett JS, Rohatagi S, DeWitt KE, Morales RJ, DiSanto AR. The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride). Am J Ther. 1996 Apr; 3(4):298-313. PMID: 11862265.
    Citations:    
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Barrett's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (437)
Explore
_
Co-Authors (2)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.